Biomerica (Biomerica) Interest Expense : $0.00 Mil (TTM As of Feb. 2024)

View and export this data going back to 1978. Start your Free Trial

What is Biomerica Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biomerica's interest expense for the three months ended in Feb. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biomerica's Operating Income for the three months ended in Feb. 2024 was $ -2.00 Mil. Biomerica's Interest Expense for the three months ended in Feb. 2024 was $ 0.00 Mil. GuruFocus does not calculate Biomerica's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biomerica Interest Expense Historical Data

The historical data trend for Biomerica's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Interest Expense Chart

Biomerica Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Interest Expense

Get a 7-Day Free Trial

Biomerica Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Biomerica Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Biomerica (NAS:BMRA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biomerica's Interest Expense for the three months ended in Feb. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Feb. 2024 was $-2.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2024 was $0.54 Mil.

Biomerica's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as

GuruFocus does not calculate Biomerica's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Biomerica Inc has enough cash to cover all of its debt. Its financial situation is stable.

Biomerica (Biomerica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

17571 Von Karman Avenue, Irvine, CA, USA, 92614

Website

https://www.biomerica.com

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.

Executives

John P. Kenny	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani	director, officer: Cheif Executive Officer	17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu	officer: Chief Financial Officer	12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri	director
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan	officer: Chief Financial Officer	114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio	officer: President-diagnostics	1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore	director, 10 percent owner, officer: Secretary	1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson	director	1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider	other: Greater than 5% holder	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The	other: Greater than 5% holder	7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm	director	1533 MONROVIA AVE., NEWPORT BEACH CA 92663